Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • The Alfred Hospital is trialing Rhythm’s technology ColoSTAT a blood test that helps detect bowel cancer at its early stages.
  • Alfred will be the third hospital to be trialing the technology

The Alfred Hospital is trailing Rhythm BioSciences ColoSTAT which helps detect bowel cancer at its early stages.

ColoSTAT is a cost effective blood test which is used for detecting early stages of bowel cancer, giving patients another option than screening programs.

Melbournes Alfred Hospital will be the third hospital to be trialling ColoSTAT, with the first patients arriving in the next few months. Alfred Hospital has a long history of supporting clinical trials and bowel cancer research.

According to Bowel Cancer Australia, Australia has one of the highest rates of Bowel cancer in the world and is it is the second biggest cancer killer. If detected early it could be treated successfully.

Rhythm Biosciences develops and sells Australian medical technology to national and international markets. ColoSTAT is the first proposed technology for detecting the early stages of bowel cancer for the company and is expected to cut healthcare costs.

Rhythm CEO, Glenn Gilbert is looking forward with the clinical trial at Alfreds.

“Working with The Alfred adds to the credibility of this clinical trial and we look
forward to this collaboration and ultimately the results,” he said.

RHY by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug